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ABSTRACT
Background: In studying the therapeutic
evidence of innovative drug treatments,
increasing attention is being devoted to
differentiating between results that indicate no
significant differences among the treatments
under examination (‘‘no proof of difference’’)
and results that demonstrate the therapeutic
equivalence among the treatments (‘‘proof of no
difference’’).
Aim: Our analysis was aimed at evaluating the
degree of therapeutic equivalence for
dipeptidylpeptidase-4 (DPP-4) inhibitors given
in type 2 diabetes as monotherapy or in
combination with metformin.
Methods: Equivalence was determined by
developing a standard Forest plot that
incorporated the information on margins
previously reported in randomized trials on
these agents. The end point was HbA1c change
from baseline; the equivalence margin was set at
±0.25% change in HbA1c. The clinical material
was obtained from a systematic review on this
topic.
Results: Given as monotherapy, linagliptin,
sitagliptin, and vildagliptin (but not
saxagliptin) met the equivalence criterion
when compared with one another. Given in
combination with metformin, linagliptin,
saxagliptin, sitagliptin, and vildagliptin
showed an equivalent effect whereas alogliptin
did not satisfy the equivalence criterion.
Conclusions: Considering the most recent
therapeutic guidelines, our results are of
interest particularly as regards the information
on DPP-4 inhibitors in combination with
metformin. Four of the five DPP-4 inhibitors
under examination clearly showed to have the
same effectiveness; the fifth agent—alogliptin—
failed to meet the equivalence criterion, but only
because its superiority could not be excluded.
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In studying the therapeutic evidence of
innovative drug treatments, increasing
attention is being devoted to differentiating
between results that indicate no significant
differences among the treatments under
examination (‘‘no proof of difference’’) and
results that demonstrate the therapeutic
equivalence among the treatments (‘‘proof of
no difference’’). It is well known that this latter
conclusion is more informative than the former
because ‘‘proof of no difference’’ is a conclusive
result whereas ‘‘no proof of difference’’ is an
inconclusive one [1–3].
No such analysis has thus far been conducted
concerning dipeptidylpeptidase-4 (DPP-4)
inhibitors that represent a pharmacological
class increasingly employed in patients with
type 2 diabetes.
In this study, we re-analyzed the clinical
material presented in the most recent and most
exhaustive systematic review in this area [4] to
quantify the degree of therapeutic equivalence
for DPP-4 inhibitors given in this disease
condition as monotherapy or in combination
with metformin.
Our clinical material included the results
of all direct and indirect meta-analytical
comparisons that Craddy and co-workers [4]
have published in their recent systematic
review on this topic. Testing equivalence is
particularly straightforward when the
information on margins is combined with
standard Forest plots [5, 6]. Margins represent a
threshold between clinically relevant
incremental benefits and irrelevant ones, and
can be retrieved from statistical power
information of original trials.
We have applied this approach to evaluate
the equivalence of monotherapy with
alogliptin, linagliptin, saxagliptin, sitagliptin
or vildagliptin versus placebo (Fig. 1a) and the
equivalence of the same agents in combination
with metformin versus metformin alone
(Fig. 1b). The end point was HbA1c change
from baseline. The equivalence margins were
set at ±0.25% change in HbA1c according to
Buse et al. [7]. The clinical material that was
reported by Craddy et al. [4] is presented in their
Table 5.
In our first analysis (Fig. 1a), our equivalence
testings found an equivalent treatment effect
for linagliptin, sitagliptin, and vildagliptin
given as monotherapy when compared with
one another; the effect of saxagliptin did not
satisfy the equivalence criterion, while the
result for alogliptin was borderline. In our
second analysis (Fig. 1b), the combination of
the same five agents in comparison with
metformin alone showed an equivalent effect
for linagliptin, saxagliptin sitagliptin, and
vildagliptin whereas the combination
including alogliptin did not satisfy the
equivalence criterion.
It should be kept in mind that, in patients
with type 2 diabetes, all international guidelines
advocate metformin first. Hence, our analysis on
monotherapy with DPP-4 inhibitors had more
speculative than a practical interest. In contrast,
the analysis evaluating the combination of DPP-4
inhibitors with metformin had some practical
interest. In fact, four of the five DPP-4 inhibitors
clearly showed to have the same effectiveness; the
fifth agent—alogliptin—failed to meet the less
important criterion of the ‘‘left’’ margin (so that
its superiority cannot be excluded), but, however,
fully satisfied the criterion of being non-inferior
in comparison with the ‘‘right’’ margin.
While the safety of these drugs is another
important factor for defining their respective
role in comparative terms, the evidence on this
point seems to be more difficult to interpret
because of the diversity of the safety end points
and their relatively low frequency of occurrence
[4].
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In conclusion, although our analyses have
entirely been based on the same clinical
material already published by Craddy et al. [4],
our results convey original information to
better interpret the effectiveness of these
agents in terms of equivalence. When
Fig. 1 Forest plot with equivalence margins: relative
treatment effect of ﬁve DDP4 inhibitors evaluated as
monotherapy versus placebo (a) or as combination with
metformin versus metformin alone (b). Incremental
effectiveness is expressed according to the end point of
HbA1c change from baseline. In both panels, the horizontal
bars (alogliptin in violet, linagliptin in yellow, saxagliptin in
red, sitagliptin in green, vildagliptin in blue) indicate the
two-sided 95% conﬁdence interval for the meta-analytic
estimate (solid square) of relative treatment effect. The
equivalence interval is comprised between the two vertical
dotted lines and is centered around the value of weighted
incremental effectiveness (vertical solid line) across the ﬁve
agents (-0.71 in a, -0.61 in b). The equivalence test is
applied based on the equivalence intervals that reﬂect the
margins reported by Buse et al. [7]. The criterion for
demonstrating equivalence (at alpha level = 2.5%) is when
the entire 95% conﬁdence interval remains within the
equivalence interval. P values for equivalence were: a (top
to bottom) 0.038, 0.024, 0.177, 0.002, 0.023; b (top to
bottom) 0.103, 0.01, 0.003, 0.001, 0.002
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treatment with a DPP-4 inhibitor in
combination with metformin is started in a
given patient, our findings indicate that the
magnitude of the reduction in HbA1c cannot
represent the main criterion for selecting a
specific agent in a given patient, since the
expected improvement is essentially the same
across these agents. Other criteria should,
therefore, prevail, including the dosing
schedule, the profile of adverse effects, and,
last but not least, the cost.
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